prulifloxacin has been researched along with carbostyril in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 26 (44.83) | 18.2507 |
| 2000's | 32 (55.17) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kimura, K; Kise, M; Kitano, M; Matsuda, M; Nishino, T; Otsuki, M; Ozaki, M; Segawa, J; Shibata, K; Tomii, Y | 1 |
| Kosuge, K; Morino, A; Nakashima, M; Okuyama, Y; Ozaki, M; Takebe, Y; Uematsu, T | 1 |
| Mitsuhashi, S; Yoshida, T | 1 |
| Ito, K; Izumi, K; Kawazoe, K; Mikamo, H; Tamaya, T | 1 |
| Ishimoto, K; Iwakura, S; Murakami, K; Tanimura, H; Uchiyama, K | 1 |
| Ishibashi, S; Iwakura, K; Kawaminami, A; Shindo, Y; Sumi, N; Tawaratani, T; Uchimoto, H; Yoshida, M | 1 |
| Akune, A; Asaoka, H; Chihaya, Y; Ihara, T; Nagata, R; Nakama, K; Shindo, Y; Sumi, N | 1 |
| Fujii, S; Furukawa, S; Kikumori, M; Morinaga, T; Shindo, Y; Sumi, N; Watanabe, M; Yasuhira, K | 3 |
| Fujii, S; Kikumori, M; Morinaga, T; Nishimori, T; Okazaki, I; Shindo, Y; Sumi, N; Watanabe, M | 1 |
| Nakamura, T; Nakasuji, T; Sakai, K; Shindo, Y; Sumi, N; Tateda, C; Yamakawa, S | 1 |
| Ando, M; Iwakura, K; Kojima, M; Shindo, Y; Sumi, N; Tamura, H; Watanabe, M; Yamashita, Y | 1 |
| Asaoka, H; Inoue, T; Ishihara, M; Ishimura, K; Kamata, K; Ogawa, A; Shindo, Y; Sumi, N | 1 |
| Ishibashi, S; Iwakura, K; Kakemi, K; Kawaminami, A; Matsuyama, S; Oka, T; Shindo, Y; Sumi, N; Tawaratani, T | 1 |
| Ishikawa, Y; Iwakura, K; Nishiguchi, Y; Shimazu, H; Shindo, Y; Sumi, N; Yoshida, M | 1 |
| Fukuda, K; Iwakura, K; Nishimura, N; Shindo, Y; Sumi, N; Tamura, K; Yamazaki, S | 1 |
| Ide, M; Iwakura, K; Nagatani, M; Oda, S; Shindo, Y; Sumi, N; Tamura, K | 1 |
| Ishibashi, S; Iwakura, K; Nakazawa, M; Shindo, Y; Sumi, N; Tawaratani, T; Uchimoto, H; Yoshida, M | 1 |
| Ajisawa, A; Akao, M; Banba, T; Fukuda, H; Fukuyama, M; Hosoda, S; Irimajiri, S; Kato, H; Kim, Y; Masuda, G; Murata, M; Nakagawa, M; Negishi, M; Nitta, Y; Obana, M; Ohkubo, H; Ohnishi, K; Sagara, H; Sajima, Y; Sasaki, M; Takizawa, Y; Tomizawa, I; Tsunoda, T; Yamaguchi, T; Yoshikawa, K | 1 |
| Adachi, T; Honmura, T; Matsuda, M; Nishimura, I; Nishino, T; Okawa, Y; Ozaki, M; Tomii, Y; Yamaguchi, R | 1 |
| Momota, K; Morino, A; Okuyama, Y | 2 |
| Morino, A; Okuyama, Y | 1 |
| Fujimura, S; Kikuchi, T; Lutfor, AB; Nukiwa, T; Shoji, S; Takahashi, H; Tokue, Y; Watanabe, A | 1 |
| Morino, A; Nakamura, A; Okuyama, Y; Tougou, K; Watanabe, S | 1 |
| Bonino, A; Carlone, NA; Cuffini, AM; Mandras, N; Palarchio, AI; Roana, J; Rossi, V; Tullio, V | 1 |
| Eda, T; Hosaka, M; Hoshino, K; Inoue, M; Kaieda, S; Kitasato, H; Kuga, A; Okamoto, R; Sato, Y; Seto, I | 1 |
| Mingoia, M; Montanari, MP; Varaldo, PE | 1 |
| Mirelis, B; Miró, E; Navarro, F; Prats, G; Roig, C | 1 |
| Dionisio, P; Grassi, C; Rosignoli, MT; Salvatori, E | 1 |
| Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
| Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
| Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
| Brion, N; Dionisio, P; Gualano, V; Marchetti, M; Millérioux, L; Picollo, R; Rosignoli, MT | 1 |
| Ciottoli, GB; Crumb, WJ; Durando, L; Lacroix, P | 1 |
| Keam, SJ; Perry, CM | 1 |
| Carmignani, G; De Rose, AF; Dionisio, P; Olivieri, L; Rosignoli, MT; Salvatori, E | 1 |
| Cochetti, I; Ferrante, L; Montanari, MP; Rossi, V; Tili, E; Varaldo, PE | 1 |
| Marchese, A; Roveta, S; Schito, AM; Schito, GC | 1 |
| Allegra, L; Cazzola, M; Dionisio, P; Salvatori, E | 1 |
| Matera, MG | 1 |
| Allegranzi, B; Ciottoli, GB; Concia, E; Dionisio, P; Marchetti, M; Orticelli, G | 1 |
| Mirelis, B; Prats, G; Rossi, V; Salvatori, E | 1 |
| Guo, L; Jin, X; Qi, M; Wang, P; Zhao, H | 1 |
| Bolis, P; Cromi, A; Ghezzi, F; Salvatore, S; Serati, M; Uccella, S | 1 |
| De Sarro, G; Gallelli, A; Gallelli, L; Maselli, R; Pelaia, G; Roccia, F; Vero, G | 1 |
| Cheng, Y; Fang, Y; Ma, M; Qu, H; Xu, P; Xu, T; Xu, Z | 1 |
| Gualco, L; Marchese, A; Schito, AM; Schito, GC | 1 |
| Esposito, S; Ianniello, F; Leone, S; Noviello, S | 1 |
| Mari, M | 1 |
| Barbone, F; De Maria, M; Giannarini, G; Manassero, F; Mogorovich, A; Morelli, G; Selli, C; Valent, F | 1 |
| Barattè, S; Dionisio, P; Gorlero, F; Lorenzi, P; Picollo, R; Rosignoli, MT; Ruggieri, A | 1 |
| Aoki, M; Iguchi, M; Kato, Y; Kurosawa, T; Shibasaki, S; Tsuji, A; Yagi, Y | 1 |
| Ida, T; Kariyama, R; Kato, Y; Kumon, H; Maebashi, K; Mikuniya, T; Monden, K | 1 |
| Aliberti, S; Allegra, L; Blasi, F; Centanni, S; Santus, P; Tarsia, P | 1 |
| Agnello, C; Cacciatore, A; Caruso, S; Cianci, A; Di Mari, L; Mammana, G | 1 |
4 review(s) available for prulifloxacin and carbostyril
| Article | Year |
|---|---|
Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis.
Topics: Anti-Infective Agents; Bronchitis, Chronic; Dioxolanes; Female; Fluoroquinolones; Humans; Male; Piperazines; Quinolones | 2006 |
Pharmacologic characteristics of prulifloxacin.
Topics: Anti-Infective Agents; Bacteria; Dioxolanes; Fluoroquinolones; Humans; Piperazines; Quinolones | 2006 |
Prulifloxacin: a new antibacterial fluoroquinolone.
Topics: Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topic; Community-Acquired Infections; Cross Infection; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Piperazines; Quinolones; Respiratory Tract Infections; Treatment Outcome | 2006 |
Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis.
Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Dioxolanes; Fluoroquinolones; Humans; Piperazines; Prodrugs; Quinolones | 2007 |
13 trial(s) available for prulifloxacin and carbostyril
| Article | Year |
|---|---|
Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Dioxolanes; Drug Administration Schedule; Fluoroquinolones; Food; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Piperazines; Prodrugs; Quinolones | 1994 |
NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
Topics: Administration, Oral; Anti-Infective Agents; Bacteria; Bacterial Infections; Dioxolanes; Female; Fluoroquinolones; Genital Diseases, Female; Genitalia, Female; Humans; Microbial Sensitivity Tests; Piperazines; Pregnancy; Quinolones | 1995 |
Penetration of NM441, a new quinolone, into human bile and gallbladder tissue.
Topics: Anti-Infective Agents; Bile; Cholecystectomy; Dioxolanes; Fluoroquinolones; Gallbladder; Humans; Piperazines; Quinolones | 1995 |
[Clinical study of prulifloxacin on infectious enteritis. Japan Research Committee of Prulifloxacin, Research Group on Infectious Enteritis].
Topics: Adult; Anti-Infective Agents; Bacteria; Dioxolanes; Drug Resistance, Microbial; Enteritis; Female; Fluoroquinolones; Humans; Male; Piperazines; Quinolones | 1996 |
Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Dioxolanes; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Quinolones; Treatment Outcome | 2002 |
Pharmacokinetics and tolerability of prulifloxacin after single oral administration.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cross-Over Studies; Dioxolanes; Fluoroquinolones; Half-Life; Humans; Male; Piperazines; Quinolones; Spectrophotometry, Ultraviolet | 2003 |
Prulifloxacin.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Bronchitis, Chronic; Ciprofloxacin; Clavulanic Acid; Dioxolanes; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Half-Life; Humans; Italy; Molecular Structure; New Zealand; Pefloxacin; Piperazines; Prodrugs; Quinolones; Urinary Tract Infections | 2004 |
Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Quinolones; Treatment Outcome; Urinary Tract Infections | 2005 |
Penetration of orally administered prulifloxacin into human lung tissue.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Dioxolanes; Female; Fluoroquinolones; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Piperazines; Pneumonectomy; Quinolones | 2005 |
[Single dose versus 5-day course of oral prulifloxacin in antimicrobial prophylaxis for transrectal prostate biopsy].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Biopsy; Dioxolanes; Drug Administration Schedule; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Prostate; Prostatic Neoplasms; Quinolones | 2007 |
Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial.
Topics: Adult; Anti-Bacterial Agents; Chronic Disease; Dioxolanes; Double-Blind Method; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Piperazines; Prospective Studies; Prostatitis; Quinolones | 2007 |
Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Biological Assay; Calibration; Dioxolanes; Endometrium; Fallopian Tubes; Female; Fluoroquinolones; Genitalia, Female; Humans; Hysterectomy; Male; Middle Aged; Piperazines; Quinolones; Reproducibility of Results; Vagina | 2007 |
[Antibiotic prophylaxis with prulifloxacin in women undergoing induced abortion: a randomized controlled trial].
Topics: Abortion, Induced; Adolescent; Adult; Antibiotic Prophylaxis; Curettage; Dioxolanes; Female; Fluoroquinolones; Gestational Age; Humans; Incidence; Parity; Pelvic Infection; Pelvic Inflammatory Disease; Piperazines; Pregnancy; Quinolones; Time Factors | 2008 |
41 other study(ies) available for prulifloxacin and carbostyril
| Article | Year |
|---|---|
In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dogs; Drug Evaluation, Preclinical; Enoxacin; Female; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Prodrugs; Quinolones; Respiratory Tract Infections; Streptococcal Infections; Urinary Tract Infections | 1991 |
Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Dioxolanes; Enoxacin; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Topoisomerase II Inhibitors | 1993 |
[A 13-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 5-week recovery test].
Topics: Administration, Oral; Alanine Transaminase; Animals; Anti-Infective Agents; Aspartate Aminotransferases; Beta-Globulins; Body Weight; Cartilage, Articular; Dioxolanes; Dogs; Dyskinesia, Drug-Induced; Female; Fluoroquinolones; gamma-Globulins; Male; Piperazines; Quinolones | 1996 |
[Single and 4-week oral toxicity studies of prulifloxacin (NM441) in aged dogs].
Topics: Administration, Oral; Age Factors; Alanine Transaminase; Animals; Anti-Infective Agents; Aspartate Aminotransferases; Blood Urea Nitrogen; Creatinine; Dioxolanes; Dogs; Drinking; Eating; Female; Fluoroquinolones; Leukocyte Count; Male; Nephritis, Interstitial; Piperazines; Quinolones; Vomiting; Weight Loss | 1996 |
[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(1)--A fertility study in rats by oral administration].
Topics: Administration, Oral; Animals; Anti-Infective Agents; Cecum; Dioxolanes; Drinking; Eating; Embryonic and Fetal Development; Female; Fertility; Fluoroquinolones; Kidney; Male; Organ Size; Piperazines; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley | 1996 |
[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(2)--A teratogenicity study in rats by oral administration].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Anti-Infective Agents; Cecum; Dioxolanes; Drinking; Eating; Embryonic and Fetal Development; Female; Fluoroquinolones; Kidney; Male; Organ Size; Piperazines; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley; Reproduction; Weight Gain | 1996 |
[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(3)--A teratogenicity study in rabbits by oral administration].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Anti-Infective Agents; Cecum; Dioxolanes; Drinking; Eating; Embryonic and Fetal Development; Female; Fetal Death; Fluoroquinolones; Humans; Male; Organ Size; Piperazines; Pregnancy; Quinolones; Rabbits; Reproduction; Weight Gain | 1996 |
[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(4)--A perinatal and postnatal study in rats by oral administration].
Topics: Administration, Oral; Animals; Animals, Newborn; Anti-Infective Agents; Cecum; Dioxolanes; Drinking; Eating; Embryonic and Fetal Development; Female; Fluoroquinolones; Lactation; Male; Organ Size; Piperazines; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley; Reproduction; Weight Gain | 1996 |
[Antigenicity studies of prulifloxacin (NM441)].
Topics: Anaphylaxis; Animals; Anti-Infective Agents; Antigens; Dioxolanes; Female; Fluoroquinolones; Freund's Adjuvant; Guinea Pigs; Male; Mice; Mice, Inbred C57BL; Passive Cutaneous Anaphylaxis; Piperazines; Quinolones; Rats; Serum Albumin; Serum Albumin, Bovine | 1996 |
[Mutagenicity studies of prulifloxacin (NM441) and the active metabolite (NM394)].
Topics: Animals; Anti-Infective Agents; Chromosome Aberrations; Cricetinae; Dioxolanes; Escherichia coli; Fluoroquinolones; Humans; Male; Mice; Mice, Inbred Strains; Micronucleus Tests; Mutagenicity Tests; Piperazines; Quinolones; Salmonella typhimurium | 1996 |
[A photoallergenicity study of prulifloxacin (NM441) in guinea pigs].
Topics: Animals; Anti-Infective Agents; Dermatitis, Photoallergic; Dioxolanes; Fluoroquinolones; Guinea Pigs; Male; Piperazines; Quinolones; Ultraviolet Rays | 1996 |
[Renal toxicity of prulifloxacin (NM441) in rats].
Topics: Administration, Oral; Animals; Anti-Infective Agents; Crystallization; Dioxolanes; Female; Fluoroquinolones; Kidney; Kidney Tubular Necrosis, Acute; Kidney Tubules; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley | 1996 |
[Single-dose toxicity studies of prulifloxacin (NM441) in mice, rats and dogs and the active metabolite (NM394) in rats].
Topics: Administration, Oral; Animals; Anti-Infective Agents; Dioxolanes; Dogs; Female; Fluoroquinolones; Injections, Intraperitoneal; Injections, Intravenous; Injections, Subcutaneous; Lethal Dose 50; Male; Mice; Mice, Inbred Strains; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley | 1996 |
[A 4-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 4-week recovery test].
Topics: Administration, Oral; Animals; Anti-Infective Agents; Cecum; Chlorides; Dioxolanes; Drinking; Eating; Female; Fluoroquinolones; gamma-Globulins; Kidney Tubular Necrosis, Acute; Male; Organ Size; Piperazines; Potassium; Quinolones; Rats; Rats, Sprague-Dawley; Weight Gain | 1996 |
[A 4-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 4-week recovery test].
Topics: Administration, Oral; Alanine Transaminase; Alpha-Globulins; Animals; Anti-Infective Agents; Cartilage, Articular; Dioxolanes; Dogs; Dyskinesia, Drug-Induced; Female; Fluoroquinolones; Kidney; Leukocyte Count; Male; Piperazines; Quinolones | 1996 |
[A 13-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 5-week recovery test].
Topics: Administration, Oral; Animals; Anti-Infective Agents; Blood Proteins; Blood Urea Nitrogen; Cartilage, Articular; Cecum; Chlorides; Dioxolanes; Female; Fluoroquinolones; Kidney Tubular Necrosis, Acute; Male; Organ Size; Piperazines; Potassium; Quinolones; Rats; Rats, Sprague-Dawley; Triglycerides | 1996 |
Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Area Under Curve; Dioxolanes; Escherichia coli Infections; Fluoroquinolones; Half-Life; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Piperazines; Quinolones; Urinary Tract Infections | 1996 |
Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Autoradiography; Biotransformation; Dioxolanes; Dogs; Female; Fluoroquinolones; Food-Drug Interactions; Half-Life; Injections, Intravenous; Intestinal Absorption; Macaca fascicularis; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Sex Characteristics; Tissue Distribution | 1997 |
Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats.
Topics: Animals; Anti-Infective Agents; Autoradiography; Biotransformation; Dioxolanes; Feces; Female; Fluoroquinolones; Liver; Male; Maternal-Fetal Exchange; Milk; Piperazines; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley; Tissue Distribution | 1997 |
Pharmacokinetics of prulifloxacin. 3rd communication: metabolism in rats, dogs and monkeys.
Topics: Animals; Anti-Infective Agents; Bile; Biotransformation; Chromatography, High Pressure Liquid; Dioxolanes; Dogs; Feces; Fluoroquinolones; Macaca fascicularis; Male; Mass Spectrometry; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley | 1997 |
Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.
Topics: Anti-Infective Agents; Dioxolanes; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Genes, Bacterial; Humans; Piperazines; Point Mutation; Polymerase Chain Reaction; Quinolones; Staphylococcus aureus | 1998 |
Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent.
Topics: Amino Acid Sequence; Animals; Anti-Infective Agents; Aryldialkylphosphatase; Dioxolanes; Esterases; Fluoroquinolones; Humans; Hydrolysis; Male; Mice; Microsomes, Liver; Molecular Sequence Data; Piperazines; Prodrugs; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Sequence Homology, Amino Acid | 1998 |
Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with pefloxacin.
Topics: Animals; Anti-Infective Agents; Cell Survival; Dioxolanes; Fluoroquinolones; In Vitro Techniques; Klebsiella pneumoniae; Macrophages, Peritoneal; Male; Mice; Microbial Sensitivity Tests; Pefloxacin; Phagocytosis; Piperazines; Quinolones | 2000 |
[In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Topics: Anti-Infective Agents; Bacteria; Dioxolanes; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Piperazines; Quinolones; Respiratory Tract Infections; Sepsis | 2000 |
In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
Topics: Anti-Infective Agents; Community-Acquired Infections; Cross Infection; Dioxolanes; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Italy; Microbial Sensitivity Tests; Piperazines; Quinolones | 2001 |
In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.
Topics: Anti-Infective Agents; Dioxolanes; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Piperazines; Quinolones | 2002 |
Prulifloxacin. NAD-441A, NM 441, Quisnon.
Topics: Animals; Anti-Infective Agents; Dioxolanes; Drug Interactions; Enteritis; Fluoroquinolones; Humans; Male; Mice; Piperazines; Prostatitis; Quinolones; Respiratory Tract Infections; Surgical Wound Infection | 2002 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Ciprofloxacin; Dioxolanes; DNA-Binding Proteins; Dogs; Fluoroquinolones; In Vitro Techniques; Moxifloxacin; Patch-Clamp Techniques; Piperazines; Potassium Channel Blockers; Quinolines; Quinolones; Telemetry; Trans-Activators; Transcriptional Regulator ERG | 2003 |
Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin.
Topics: Colony Count, Microbial; Culture Media, Conditioned; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Piperazines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones | 2005 |
Determination of the active metabolite of prulifloxacin in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Anti-Bacterial Agents; Calibration; Chromatography, Liquid; Dioxolanes; Fluoroquinolones; Humans; Piperazines; Quinolones; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2006 |
Prophylactic single-dose prulifloxacin for catheter-associated urinary tract infection after tension-free vaginal tape procedure.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteriuria; Dioxolanes; Female; Fluoroquinolones; Humans; Middle Aged; Piperazines; Quinolones; Suburethral Slings; Urinary Catheterization; Urinary Incontinence, Stress; Vagina | 2007 |
Acute renal failure probably induced by prulifloxacin in an elderly woman : a first case report.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Dioxolanes; Female; Fluoroquinolones; Humans; Piperazines; Quinolones | 2006 |
Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study.
Topics: Anti-Bacterial Agents; Dendrimers; Dioxolanes; Drug Carriers; Escherichia coli; Fluoroquinolones; Piperazines; Polyamines; Quinolizines; Quinolones | 2007 |
In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Topics: Anti-Infective Agents, Urinary; Bacterial Adhesion; Ciprofloxacin; Dioxolanes; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Hemolysin Proteins; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Ultraviolet Rays; Urinary Tract Infections | 2007 |
[In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dioxolanes; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Staphylococcus aureus; Urinary Tract Infections | 2006 |
Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin, in rats.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Biological Transport; Biotransformation; Carrier Proteins; Dioxolanes; Fluoroquinolones; Hepatocytes; Injections, Intravenous; Liver; Male; Membrane Transport Modulators; Metabolic Clearance Rate; Models, Biological; Piperazines; Prodrugs; Quinolones; Rats; Rats, Sprague-Dawley | 2007 |
Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Catheters, Indwelling; Dioxolanes; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Fosfomycin; Humans; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Piperazines; Polyethylene; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Rats; Urinary Catheterization; Urinary Tract Infections | 2007 |